CoChat

Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study

Open access
Jaiswal, Mamta, Martin, Catherine L., Brown, Morton B., Callaghan, Brian, Albers, James W., Feldman, Eva L., Pop-Busui, Rodica · 2015 · Journal of Diabetes and its Complications
Cited by 96

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Objective Experimental studies have reported potential benefit of glucagon-like peptide-1(GLP-1) receptor agonists in preventing diabetic peripheral neuropathy (DPN). We therefore performed a proof-of-concept pilot study to evaluate the effect of exenatide, a GLP-1 agonist, on measures of DPN and cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes (T2D). Research Design and Methods Forty-six T2D subjects (age 54±10 years, diabetes duration 8 ± 5 years,HbA1c 8.2 ±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n= 24). The subjects, with similar HbA1c levels, were followed for 18 months. The primary end point was the prevalence of confirmed clinical neuropathy (CCN). Changes in measures of CAN, other measures of small fiber neuropathy such as intra-epidermal nerve fiber density (IENFD), and quality of life were also analyzed. Results Glucose control was similar in both groups during the study. There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices. Conclusions In this pilot study of patients with T2D and mild to moderate DPN, 18 months of exenatide treatment had no significant effect on measures of neuropathy compared with glargine treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jdiacomp.2015.07.013

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 96

Metadata

Authors
Jaiswal, M., Martin, C. L., Brown, M. B., Callaghan, B., Albers, J. W., Feldman, E. L., & Pop-Busui, R.
Venue
Journal of Diabetes and its Complications
Publisher
Elsevier BV
Published
2015-11
Volume
29
Issue
8
Pages
1287-1294
ISSN
  • 0891-6632 (ISSN-L)
  • 1056-8727
OpenAlex
W972810958
Cited by
96
References
8
FWCI
2.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.